Draft:Spasmolytic A29
Review waiting, please be patient.
This may take 8 weeks or more, since drafts are reviewed in no specific order. There are 1,823 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
The topic of this draft may not meet Wikipedia's general notability guideline. |
Identifiers | |
---|---|
CAS Number |
|
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C18H21N |
Molar mass | 251.373 g·mol−1 |
3D model (JSmol) | |
|
Structure called A29 here:[1][2]
A-29 is not used by itself but is co-administered with ketobemidone in a formulation that is called Ketogan. A29 is a regioisomer of amitriptyline with the bridge ethylene removed. The pharmacology is stated to be NMDA antagonist and not sodium channel blocker activity.
Similar pharmacological compounds to consider include: BW 247 and DPH-362.
References
[edit]- ^ PETERSEN PV (1951). "Studies on a new spasmolytic compound 1,1-diphenyl-3-dimethylaminobutene-1 (A29), related to methadone, and on the combined use of this compound and a potent analgesic, ketobemidone (A21)". Acta Pharmacologica et Toxicologica. 7 (1): 51–64. doi:10.1111/j.1600-0773.1951.tb02849.x. PMID 14829296.
- ^ Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H (September 1998). "Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists". Biochemical Pharmacology. 56 (5): 553–9. doi:10.1016/s0006-2952(98)00088-4. PMID 9783723.